News NICE says no to Ipsen’s kidney cancer drug NICE has issued draft guidance which rejects Ipsen's Cabometyx for NHS use in previously treated advanced renal cell carcinoma (RCC).
News Merrimack goes back to drawing board with $1bn Ipsen sell-of... Merrimack sells off Onivyde and generic cancer drug
News Ipsen/Exelixis' drug approved in EU for kidney cancer Cabometyx secures new indication in renal cell carcinoma.
Views & Analysis Ipsen: future of healthcare is digital – but some at risk of... Risk of a 'two speed' healthcare because of digital inequality
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.